Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 14, 2005 Charly Travers	Dueling Fools: Protein Design Labs Bull Protein Design Labs is a great company for biotech investors. It has a diverse and growing revenue stream, will turn cash-flow positive next year, and has some potential winners in its pipeline to increase the company's value for long-term-minded shareholders.
The Motley Fool August 29, 2007 Brian Lawler	PDL Lands in a Hazard The biopharma announces a dramatic shift following the failure of its lead drug. Shares of PDL are down only 19% this morning, presumably because the thought of a leaner and thriftier PDL with its royalty-generating potential is a welcome relief to some investors.
The Motley Fool February 25, 2005 Charly Travers	Protein Design Labs' Future A look ahead to a transitional year -- and how much the ESP Pharma acquisition will boost revenues -- coming Monday.
The Motley Fool March 15, 2005 Charly Travers	PDL Eyeing Up Profits A timely acquisition is paying off for this drug maker. Investors, take note.
The Motley Fool August 5, 2005 Charly Travers	No Surprise Over PDL's Upside Protein Design Labs' overwhelmingly positive earnings release is good news for shareholders.
The Motley Fool May 3, 2005 Charly Travers	PDL's Well-Stocked Pipeline A broad drug portfolio makes this biotech, Protein Design Labs, a long-term winner.
The Motley Fool January 12, 2005 Charly Travers	Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise.
The Motley Fool February 6, 2008 Brian Lawler	PDL BioPharma Regroups, Piece by Piece The company still brings in plenty of money, despite selling off assets. Investors, take note.
The Motley Fool December 18, 2007 Brian Lawler	PDL Liquidation Sale Begins PDL BioPharma's sale of a chemotherapy drug indicates it could recoup what it paid for ESP Pharma. Investors, take note.
The Motley Fool April 14, 2008 Brian Lawler	PDL BioPharma's Split Decision PDL BioPharma is finally taking further steps to try to realize better value for the different parts of its business.
The Motley Fool February 27, 2007 Brian Lawler	PDL Keeps Us Waiting PDL BioPharma announces its year-end financial results. Investors, take note.
The Motley Fool July 14, 2005 Charly Travers	Dueling Fools: Protein Design Labs Bull Rebuttal This biotech's tomorrow is coming today. The company is a clear buy at its current market cap near $2 billion.
The Motley Fool December 13, 2004 Charly Travers	PDL Rakes It In A robust revenue stream combined with an exciting drug pipeline is this biotech's recipe for success.
The Motley Fool April 27, 2007 Brian Lawler	PDL Gets the Go-Ahead Signal The biopharma moves its lead compound into phase 3 testing. Investors, take note.
The Motley Fool November 27, 2006 Brian Lawler	Roche Says Goodbye to PDL The larger pharmaceutical drops out of daclizumab development. Investors, take note.
The Motley Fool March 28, 2005 Charly Travers	Stock Madness 2005: Protein Design Labs vs. Yahoo! Two very different Rule Breakers face off in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool March 5, 2008 Brian Lawler	PDL Taken Off the Block Yesterday, PDL BioPharma announced that it had failed to find an acquirer; instead, it will launch another round of restructuring.
The Motley Fool April 28, 2011 Brian Orelli	Buying Royalty Streams on the Cheap If management can't do it, PDL Biopharma's investors are in trouble. The trick is to find patents that are secure and a royalty stream that's predictable.
The Motley Fool August 4, 2004 Charly Travers	Labs' Report Offers Mixed Results TProtein Design Labs' royalty intake looks great, but its drug development does not.
The Motley Fool November 6, 2006 Brian Lawler	Mixed Feelings About PDL The biopharmaceutical's third-quarter results look fine on the surface, but does deeper digging reveal some reasons for investors to be concerned?
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool July 14, 2005 Stephen D. Simpson	Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great."
The Motley Fool August 2, 2007 Brian Lawler	PDL Minds Its Mild Manners The biopharma announces placid second-quarter results -- investors, take note.
The Motley Fool November 2, 2004 Charly Travers	Just the Medicine for PDL Losses are shrinking as drug royalties spur strong revenue growth.
The Motley Fool March 10, 2010 Brian Orelli	You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't.
The Motley Fool May 21, 2004 Charly Travers	Protein Design Labs' Mixed Results Protein Design Labs' Nuvion looks like a winner, while other drugs stumble. Nuvion is in early clinical development for the treatment of severe ulcerative colitis and so far the results seem particularly compelling.
The Motley Fool August 3, 2005 Charly Travers	Biotech's Big Deal The market is pleased with the partnership between Protein Design Labs and Biogen IDEC.
The Motley Fool September 28, 2007 Brian Lawler	Interview With PDL Co-Founder Cary Queen PDL BioPharma has generated much investor activism against its current management team, with some investors calling for a sale of the drugmaker. In this interview, co-founder Cary Queen discusses the current state of affairs.
The Motley Fool August 21, 2008 Brian Lawler	PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer.
The Motley Fool November 12, 2007 Brian Lawler	What's New at PDL BioPharma? The past few volatile months are reflected in the third-quarter results from PDL BioPharma. The future, however, may be smoother. Investors, take note.
The Motley Fool August 21, 2007 Brian Lawler	Change of Pace at PDL Shares of PDL BioPharma have risen more than 10% since CEO McDade announced yesterday that he would resign by the end of the year.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
The Motley Fool March 30, 2005 Travers & Smith	Stock Madness 2005: Protein Design Labs vs. Plum Creek Timber This biotech isn't as risky as you might think. But is it as solid as a tree company? Find out in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool September 20, 2007 Brian Lawler	Allergan's Overactive Acquisition Specialty pharma Allergan announced yesterday that it is acquiring privately held Esprit Pharma for $370 million in an all-cash transaction. Investors, take note.
The Motley Fool July 9, 2004 Charly Travers	Protein Design Labs' Windfall Royalties from Genentech could mean big things for PDL.
The Motley Fool March 16, 2007 Brian Lawler	PDL's Friend Comes Through PDL and partner Biogen advance one of their lead drug candidates. Investors, take note.
The Motley Fool August 18, 2008 Brian Lawler	When Breaking Up Isn't Hard to Do PDL BioPharma and Enzon are the latest biotechs looking to spin off parts of their business.
The Motley Fool May 7, 2008 Brian Lawler	PDL Delivers a Dividend The drugmaker's investors get a hefty payout.
The Motley Fool October 15, 2007 Brian Lawler	PDL BioPharma's Best Hope The data on daclizumab for multiple sclerosis is encouraging. Investors, take note.
Pharmaceutical Executive October 1, 2005 Brad Miles	Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies.
The Motley Fool May 30, 2008 Brian Lawler	PDL Shakeup Lifts Shares Shares of PDL BioPharma rise after a longtime board member, currently the company's interim CEO, departs.
The Motley Fool September 26, 2007 Brian Lawler	Shareholders Pile On Against PDL Another large shareholder has come out against the status quo at PDL BioPharma. Management resignations seen as necessary by those wanting to sell or break apart the biopharma.
The Motley Fool July 14, 2005 Stephen D. Simpson	Dueling Fools: Protein Design Labs Bear Rebuttal By looking at the price-to-book ratio, you can get a sense of just how much optimism is baked into a biotech stock. Offer the stock at $18 or below, and we'll talk. Until then, the risk-benefit analysis swings more to "risk".
The Motley Fool June 14, 2007 Brian Lawler	Dueling Fools: GlaxoSmithKline Bull Rebuttal Investors who think this pharma's market cap is too large would be missing out on the chance to own one of the best-run companies in the most exciting industry.
The Motley Fool December 31, 2007 Brian Lawler	The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007.
The Motley Fool September 24, 2007 Brian Lawler	Seismic Shifts at PDL No matter what its hedge fund owner, Third Point, decides it wants to do with PDL, one thing is clear: A year from now, PDL BioPharma will not be the same drugmaker that it is today. Investors, take note.
The Motley Fool August 22, 2006 Brian Lawler	Sticking With Myriad Genetics The potential for growth in one division offsets the risk in its trials for an Alzheimer's drug. For less risk-adverse investors, the 5% pullback in Myriad's shares Tuesday might offer a great chance to invest in this well-run company.
The Motley Fool October 31, 2006 Brian Lawler	A Biotech Frankenstock Investors, here is the perfect biotechnology beast. Cephalon... Roche... Exelixis... etc.
The Motley Fool December 7, 2011 Dan Caplinger	Has PDL BioPharma Become the Perfect Stock? Having moved from special dividends to a pure regular-dividend payout has improved income visibility for shareholders.